Evaluation of metabolic profile and C-reactive protein concentrations in brachycephalic dogs with upper airway obstructive syndrome

Paola Gianella¹*, Roberta Caccamo¹, Claudio Bellino¹, Enrico Bottero², Federica Fietta¹, Silvia Roncone¹, Fabio Ostanello³, Marco Pietra³, Paolo Buracco¹

¹ Department of Veterinary Sciences - University of Turin –Largo P. Braccini 2-5, 10095 Grugliasco – Torino - Italy
² Poliambulatorio Veterinario Argentina, Arma di Taggia, Imperia, Italy
³ Department of Veterinary Medical Sciences, University of Bologna, Via Tolara di Sopra 50, 40064 Ozzano dell’Emilia (BO), Italy

Keywords: cholesterol, fructosamine, glucose, plasma lipoprotein electrophoresis, triglycerides

List of abbreviations:
BCS body condition score
BAOS brachycephalic airway obstructive syndrome
CRP C-reactive protein
IH intermittent hypoxia
HDL high density lipoproteins
LDL low density lipoproteins
MAP mean arterial pressure
OSAS obstructive sleep apnea syndrome
SDB sleep-disordered breathing
VLDL very low density lipoproteins
*Corresponding author: Dr. Gianella Paola

Department of Veterinary Sciences, University of Turin, Largo P. Braccini 2-5, 10095 Grugliasco (Turin), Italy
Tel.: + 39 011 6709074
paola.gianella@unito.it

Conflict of interest declaration: authors declare no conflict of interest

Off-label antimicrobial declaration: author declare no off-label use of antimicrobials

Institutional animal care and use committee or other approval declaration: authors declare institutional animal care and use committee or other approval declaration were not needed for this study

Human ethics approval declaration: authors declare human ethics approval declaration was not needed

Acknowledgments:

Dr. Valeria Bonaveglio and all the veterinarians who work at the Ospedale Veterinario Universitario of the Universities of Turin and Bologna, Italy, and Dr. Gianluca Novari who works at the EmatosVetLab of Roma, Italy, are acknowledged for their assistance and contribute during data collection

Background: Brachycephalic dogs have abnormal breathing patterns similar to those in humans with obstructive sleep apnea syndrome (OSAS). Obstructive sleep apnea syndrome is associated
with dyslipidemia, hyperglycemia and insulin resistance. Despite the fact that anatomic and functional alterations are well described in brachycephalic dogs, little is known about the consequences of upper airway obstruction on systemic inflammatory response and metabolic profile.

Objectives: To describe history, clinical presentation and anatomic abnormalities; to evaluate systemic inflammatory response and metabolic profile; and to identify possible associations among clinical signs, anatomic abnormalities, inflammatory response and metabolic profile.

Animals: Thirty purebred brachycephalic dogs with brachycephalic airway obstructive syndrome (BAOS).

Methods: Prospective study. The following information was recorded and studied: respiratory/digestive signs, airway/digestive endoscopic anomalies, presence/absence of tracheal hypoplasia, histologic evaluation of gastrointestinal tract biopsy specimens, serum concentrations of C-reactive protein (CRP), fructosamine, insulin, glucose, triglyceride, cholesterol and plasma concentrations of lipoprotein classes.

Results: A high proportion of dogs (76.7%) had gastrointestinal signs. Esophageal deviation, atony of the cardia of the stomach and distal esophagitis were the most common endoscopic anomalies detected. Twenty-six (86.6%) dogs had different degree of laryngeal collapse. Gastrointestinal histologic evaluation identified mostly chronic inflammation. Glucose, fructosamine, triglycerides, cholesterol, CRP, pre-beta, beta lipoproteins and chylomicrons were increased to a variable extent. Significant associations among clinical signs, anatomic abnormalities, CRP and metabolic profile were not found.
Conclusion and clinical importance: Despite the presence of inflammation and some mild metabolic derangements, the clinicopathological variables evaluated did not offer valuable information in dogs with BAOS.
Introduction

Brachycephaly, or a shortened facial structure, is a common condition of dogs that is magnified by selective breeding. Breeds most commonly affected by brachycephalic airway obstructive syndrome (BAOS) are English and French bulldogs, Pugs and Boston terriers.¹ Most dogs with this condition develop BAOS, a chronic upper airway obstruction clinically characterized by heat stress and exercise intolerance, snoring, inspiratory dyspnea, cyanosis and, in more severe cases syncopal episodes.² In addition, gastrointestinal signs such as dysphagia, vomiting and regurgitation can develop as a consequence of the negative intrathoracic pressure generated by increased respiratory effort and aerophagia, and worsen upper esophageal, pharyngeal and laryngeal inflammation.²⁻⁴ Excessive flatulence as a consequence of aerophagia also is often present. French bulldogs often have more frequent and severe digestive signs than do pugs.⁴⁻⁷

Because medical management may only temporarily improve clinical signs and provide palliation, permitting progression of the disease to a more advanced stage,⁸ surgical treatment consisting of rhinoplasty, turbinectomy, staphylectomy, laryngeal sacculectomy or some combination of these often is required.⁹,¹⁰ Brachycephalic airway obstructive syndrome shares features of obstructive sleep apnea (OSA) in people, a form of sleep-disordered breathing characterized by recurrent collapse of the upper airway during sleep leading to intermittent hypoxia, oxygen desaturation, sleep fragmentation and arousal from sleep.¹¹,¹² Obstructive sleep apnea is prevalent in obese individuals,¹³ and is associated with decreased survival as a result of development of cardiovascular and thromboembolic disorders.¹¹,¹⁴ Moreover, growing epidemiological evidence suggests that OSA is linked to metabolic abnormalities, such as hyperglycemia, insulin resistance, type 2 diabetes and dyslipidemia.¹⁵,¹⁶ Although spontaneous OSA is very uncommon in
animals, the English bulldog has been used as an animal model of OSA because of its disordered breathing and episodes of oxygen desaturation associated with abnormal upper airway anatomy.\textsuperscript{17,18} Despite the fact that anatomic and functional alterations are well described in brachycephalic dogs,\textsuperscript{1-9, 18-22} little is known about the consequences of upper airway obstruction on the systemic inflammatory response, parameters of glucose regulation, and lipid metabolism.\textsuperscript{22-24} Thus, our prospective study was designed to: 1) describe history, clinical presentation and anatomic abnormalities; 2) evaluate the systemic inflammatory response, parameters of glucose regulation, and lipid profiles; and, 3) identify possible associations among clinical signs, anatomic abnormalities, inflammatory response, parameters of glucose regulation and lipid profiles in a series of brachycephalic dogs with BAOS.

Materials and Methods

Purebred brachycephalic dogs with BAOS presented to different veterinary teaching hospitals and referral clinics over a 2-year period were included in the study. At admission, each dog’s case history was obtained from the owner. The frequency and nature of upper respiratory (e.g., snoring, inspiratory efforts, stress or exercise intolerance, syncope) and digestive (e.g., ptyalism, regurgitation, vomiting) signs were assessed according to a previously described grading system.\textsuperscript{25} The frequency of both respiratory and digestive signs was classified as follows: never, occasionally (less than once monthly), regularly (once weekly), daily (once daily), often (more than once daily), and constantly. Inclusion of at least 1 sign in a higher grade determined the classification assigned. On the basis of the frequency of each respiratory sign, a global classification of 3 grades was assigned: grade 1 (absent or minimal), grade 2 (moderate), grade 3 (severe). The same was done for the frequency of each digestive sign.\textsuperscript{25} For each dog, a final symptomatic score from the global classifications of both upper respiratory and digestive signs was obtained. In addition to upper respiratory and
digestive signs, sleep-disordered breathing (SDB) history (e.g., night time arousals, respiratory signs and attitude after arousals, owner’s perception that sleep disruption was caused by airway obstruction, abnormal sleeping positions) was collected for each dog. The information about abnormal sleeping positions was retrospectively gleaned by telephone interview at the time of the manuscript drafting. Dogs were classified according to the presence (score 1) or absence (score 0) of at least 1 clinical sign or abnormal attitude during sleep. The frequency of night time arousals was classified arbitrarily as follows: never (score 0), mild (1 to 3 times per night; score 1), moderate to severe (≥ 4 times per night; score 2). A clinical examination was performed, body weight was recorded and a 9-point body condition score (BCS) was assigned. Physical examination and cardiac auscultation findings, echocardiographic and radiographic abnormalities, and blood test results provided evidence that no other clinically relevant diseases were present in dogs included in the study.

Aliquots of serum and plasma obtained from centrifugation of blood collected from each dog for pre-anesthetic investigations were separated and immediately stored at -20°C for biomarker analysis. Sample storage varied from 1 to 5 days. Biomarker analyses were performed in 2 different laboratories (BiEsseA s.r.l. Milan, Italy; Ematos Vet Lab s.r.l. Rome, Italy) and included evaluation of serum concentrations of fructosamine, insulin, glucose, total protein, C-reactive protein (CRP), triglycerides and cholesterol. In addition, plasma lipoprotein agarose gel electrophoresis (Hydrasis, Sebia, UK ltd) was performed using a dedicated kit (Hydragel protein, Sebia, UK ltd).

Upon signed owner consent for diagnostic and therapeutic procedures, all dogs underwent pre-surgical endoscopic evaluation of the airways (nares, rhino- and oro-pharynx, larynx, trachea and bronchi) and, if digestive signs were present, the esophagus, stomach and
duodenum. Premedication protocols were decided on a case-by-case basis (.2 mg/kg methadone alone or in combination with 10 μg/kg acepromazine). Pre-oxygenation was provided for 5 minutes before endoscopy using a face-mask. General anesthesia was induced with 2-4 mg/kg propofol IV and maintained by gas anesthesia (isoflurane or sevoflurane in 100% oxygen). Intravenous methylprednisolone sodium succinate (1 mg/kg) was given to control laryngeal edema at anesthesia induction. All endoscopic procedures were performed in standardized fashion by 3 of the authors (C.R., B.E., P.M.). In the event of gastrointestinal endoscopic evaluation, mucosal biopsy samples were collected and submitted for histologic evaluation. Rigid (2.7 mm × 18 cm, 30°; model 64029, Karl Storz Endoscopia Italia S.r.l., Verona - Italy) and flexible (6.0 mm × 103 cm; EG-1840, Pentax Italia S.r.l., Milano, Italy; 7.8 mm × 140 cm, model PV-SG 28-140, Karl Storz Endoscopia Italia S.r.l., Verona, Italy; 5.0 mm × 55 cm fiberscope; Olympus BF-P40, Olympus Medical Systems Europe GmbH, Hamburg, Germany) video endoscopes were used. Images and movies were acquired using video recording devices (Pinnacle Studio 21.5; Corel Corporation, Ottawa, Canada; Tele Pack Vet X Led, Karl Storz Endoscopia Italia S.r.l.).

Balanced isotonic crystalloid fluids were administered IV to all dogs during the entire procedure; ECG, blood pressure, and pulse oximetry were monitored continuously. During recovery, supplemental oxygen was provided as needed. The definitive diagnosis of BAOS was made by combining both upper airway respiratory signs and anatomic abnormalities, as has been described elsewhere. Laryngeal paralysis (unilateral or bilateral) was defined as a total lack of abduction of the corniculate processes of the arytenoids during inspiration.
To describe anatomic abnormalities, a quantitative anatomical scoring system was used by evaluating the following variables recorded at presentation and at the time of radiography and endoscopy: tracheal hypoplasia (tracheal diameter to the thoracic inlet ratio < 0.16), tracheal collapse, bronchial collapse, turbinate hypertrophy, stenotic nares, macroglossia or elongated tongue, elongated soft palate, thickened soft palate, nasopharyngeal collapse, altered rhynopharyngeal mucosa (hypertrophy, erosions, erythema), increased laryngopharyngeal secretions, laryngopharyngeal erosions, laryngopharyngeal nodules, and hypertrophy and eversion of the tonsils. Each variable was classified as present (score 1) or absent (score 0). A final quantitative anatomical score was obtained by the sum of each single score. In addition, the extent of laryngeal collapse was assessed endoscopically as mild (eversion of laryngeal saccules, first degree, score 1), moderate (medial displacement or overlap of the cuneiform processes, second degree, score 2) or severe (medial displacement or overlap of the corniculate processes, third degree, score 3), based on a previous classification.32

Statistical Analysis

Preliminarily, the symptomatic score was dichotomized on the basis of the median value (≤4 vs ≥5) and a 2-stage analysis was applied. In the first stage, all of the variables were tested using the \( \chi^2 \) test. Quantitative data were divided arbitrarily into 2 categories based on the medians of values. The proportion of dogs with symptomatic score ≥5 was evaluated by breed, sex, BCS, body weight, age, mean arterial pressure (MAP, mm/Hg), percent saturation of oxygen (SpO2), SDB history (i.e., night time arousals, respiratory signs and attitude after arousals, owner’s perception that sleep disruption was caused by airway obstruction, abnormal sleeping positions, presence of at least 1 clinical sign or abnormal attitude during sleep regardless of the type of clinical sign or abnormal attitude), quantitative anatomical score, laryngeal collapse score, serum concentrations of cholesterol (mg/dL), triglycerides (mg/dL),
total protein (g/dL), glucose (mg/dL), insulin (µU/ml), CRP (mg/dL), and fructosamine (µmol/L), and plasma pre-alpha (%), alpha 1 (%), alpha 2 (%), pre-beta (%), beta (%), and chylomicrons (%) lipoprotein classes.

In the second stage, factors that had \( P \) values < .20 then were evaluated using binary logistic regression. The model was based on the simultaneous entry of all variables, and its efficacy was assessed based on the likelihood ratio and the Hosmer-Lemeshow statistic. Values of \( P < .05 \) were considered significant. The odds ratio (OR) and 95% confidence intervals (95% CI) were calculated from the final binary logistic model.

All statistical analyses were performed using statistical software (IBM SPSS 25.0.0, Armonk, NY, USA).

Results

Signalment, clinical signs and laboratory data

Thirty dogs affected by BAOS were included in the study, subdivided as follow: 10 Pugs (33.3%), 13 French Bulldogs (43.3%) and 7 English Bulldogs (23.3%). Twenty-two dogs were intact males and 8 were females (4 spayed). The median age was 36.4 months (range, 10-93). The median body weight was 13.4 kg (range, 6-34). The median BCS was 6.6 (range, 5-8). The most common presenting respiratory clinical signs were snoring (28 dogs, 93.3%), increased inspiratory efforts (28 dogs, 93.3%) and stress or exercise intolerance (28 dogs, 93.3%), and syncope (7 dogs, 23.3%). Among the dogs with snoring, 16 (57.1%) snored constantly, whereas 12 (42.9%) snored with a frequency equal to or more than once daily. Among the dogs with increased inspiratory efforts, 12 (42.9%) were affected constantly, 12 (42.9%) with a frequency equal to or more than once daily, 2 (7.1%) regularly, and 2 (7.1%) occasionally. Among the dogs with stress or exercise intolerance, 5 (17.9%) had it constantly, 19 (67.9%) with a frequency equal to or
more than once daily, 1 (3.6%) regularly, and 3 (10.7%) occasionally. Among the dogs with syncope, 4 (66.7%) fainted regularly, and 3 (42.6%) occasionally. For 1 dog, the frequency of respiratory signs could not be precisely defined. Twenty-three (76.7%) dogs had gastrointestinal clinical signs in addition to respiratory clinical signs. Nineteen (76%) dogs had vomiting, 2 (10.5%) with a frequency equal to or more than once daily, 8 (42.1%) regularly, and 9 (47.4%) occasionally. Fourteen dogs (60.9%) had regurgitation, 1 (7.1%) of which regurgitated constantly, 3 (21.4%) with a frequency more than once daily, 3 (21.4%) regularly, and 7 (50%) occasionally. Eleven (47.8%) dogs had ptyalism, 1 (9.1%) of which at a frequency of once daily, 5 (45.4%) regularly, and 5 (45.4%) occasionally. Twenty (66.7%) dogs experienced night time arousals, with mild and moderate to severe frequency in 12 (60%) and 8 (40%) dogs, respectively. For 17 (85%) dogs, the owner’s perception was that disruption of sleep was caused by the airway obstruction. Three (15%) dogs had coughing bouts after arousal, 3 (15%) panting and pacing at night, 2 (10%) loud snoring, apnea followed by abrupt arousal and reverse sneezing, and 1 (5%) reverse sneezing. Two (10%) dogs assumed abnormal sleeping positions with elevated chin. Signalment, respiratory and digestive clinical signs and SDB history can be found in supplementary information. Tables 1 and 2 show laboratory data. Results of the univariate and logistic regression analysis are found in Tables 3 and 4, respectively. Odds ratio of symptomatic score ≥5 was not significantly associated with the factors evaluated.

Evaluation of airway anatomic abnormalities and quantitative scoring system

Twenty-nine dogs underwent airway endoscopic evaluation. In 1 dog, because of clinical sign severity, endoscopic evaluation was not completed, and was followed by tracheal stent placement and surgical correction of BAOS. Twenty-nine (100%) dogs had stenotic nares and elongated soft palate, 21 (72.4%) turbinate hyperthrophy, 19 (65.5%) macroglossia, 17 (58.6%) increased
laryngopharyngeal secretions, 16 (55.2%) thickened soft palate, 13 (44.8%) nasopharyngeal collapse, 11 (37.9%) hypertrophy and eversion of the tonsils, 8 (27.6%) altered rhynopharyngeal mucosa, 6 (20.7%) laryngopharyngeal nodules, and 4 (13.8%) tracheal collapse, tracheal hypoplasia and bronchial collapse. Laryngopharyngeal erosions were not observed. Normal laryngeal function was observed in all dogs. Twenty-six (86.6%) dogs had laryngeal collapse, which was evaluated as grade 3, 2 and 1 in 2 (7.7%), 15 (57.7%) and 9 (34.6%) dogs, respectively. The remaining 3 dogs had a larynx without any degree of collapse. The median final quantitative anatomical score was 6 (range, 4-9). Results of univariate analysis of quantitative anatomical score, SDB history and laryngeal collapse score showed no statistically significant differences ($P > .05$, Table 3).

**Digestive endoscopic anomalies and histological evaluation**

Gastroduodenal endoscopy was performed in 21 (91.3%) of 23 dogs that had gastrointestinal clinical signs in addition to respiratory clinical signs. In the remaining 2 dogs, gastroduodenal endoscopy was not performed because of lack of owner consent.

Overall, all 21 dogs had ≥ 1 endoscopic esophageal, gastric or duodenal anomalies. Esophageal deviation, atony of the cardia of the stomach, distal esophagitis and precardial erosions were observed in 9 (42.9 %), 3 (14.3 %), 7 (33.3 %) and 2 (9.5 %) of cases, respectively. Gastric stasis, pyloric mucosal hyperplasia, duodenogastric reflux, diffuse erythema, punctiform inflammation, erosions and edema were observed in 6 (28.6 %), 4 (19 %), 1 (4.8 %), 7 (33.3 %), 3 (14.3 %), 1 (4.8 %) and 10 (47.6 %) dogs, respectively. Diffuse duodenal erythema, edema, mucosal irregularity and whitish tips of swollen villi were observed in 16 (76.2 %), 2 (9.5 %), 9 (42.9 %) and 2 (9.5 %) dogs, respectively.
Mucosal biopsy samples were collected from all dogs undergoing gastroduodenal endoscopy and submitted for histologic evaluation. Histologic examination was performed in all dogs according to a quantitative simplified scoring system.$^3$ Lymphocytic-plasmacytic inflammation and squamous metaplasia of the esophagus were found in 1 (4.8%) and 1 (4.8%) dogs, respectively. Lymphocytic-plasmacytic inflammation, erosions with neutrophilic inflammation, fibrosis and mucosal hyperplasia of the stomach were found in 12 (57.1%), 2 (9.5%), 2 (9.5%) and 1 (4.8%) dogs, respectively. Lymphocytic-plasmacytic inflammation, neutrophilic inflammation, lacteal dilatation and epithelial injury of the duodenum were found in 10 (47.6%), 7 (33.3%), 9 (42.9%) and 1 (4.8%) dogs, respectively.

The anatomical lesions observed can be found in the supplementary information.

Discussion

Our study provides a systematic description of the clinical presentation, as well as clinicopathological and airway anatomic abnormalities in a population of brachycephalic dogs with BAOS, and explores their possible association with systemic inflammatory response, parameters of glucose regulation and lipid profiles.

Obstructive sleep apnea describes recurrent collapse of the upper airway during sleep leading to intermittent hypoxia (IH).$^{11}$ Growing evidence from animal models of OSA suggests that IH is independently associated with metabolic dysfunction, including dyslipidemia and insulin resistance.$^{34}$

The precise mechanisms by which IH induces metabolic disturbances are not fully understood. Dyslipidemia may be caused by excessive lipolysis supplying free fatty acids to the liver, up-regulation of hepatic triglyceride biosynthesis and lipoprotein secretion.
and suppression of lipoprotein clearance.\textsuperscript{35} Insulin resistance may be caused by activation of hepatic lipid biosynthesis, activation of the sympathetic nervous system with consequent lipolysis, the hypothalamic-pituitary-adrenal axis and systemic inflammation.\textsuperscript{34,36}

Although BAOS in brachycephalic dogs is not identical to OSA in humans, important similarities exist and, because English Bulldogs have been used as a spontaneous animal model for human OSA, it would be reasonable to presume that other brachycephalic dogs may similarly be at risk for IH.

Within the study population, median age was 3 years, median BCS was 6.6 and male dogs were more common than female dogs, consistent with available literature data.\textsuperscript{22-24,48} In humans, obesity is a major risk factor for OSA and the effect of BCS has been reported as a potential aggravating factor for brachycephalic syndrome, although no correlation between BCS and the severity of upper airway obstruction has been found, as in our study.\textsuperscript{3,39,40} In human medicine, waist circumference, neck circumference and deposition of fat around specific parts of the body are considered in addition to the use of body mass index.\textsuperscript{41,42} On the contrary, in veterinary medicine, with the exception of neck girth evaluation,\textsuperscript{43,44} obesity is defined based on BCS. Therefore, additional studies considering other obesity-related parameters are needed to explore a possible correlation with increased BAOS risk, as recently found for neck girth ratio in male bulldogs.\textsuperscript{44}

Consistent with available data, snoring, inspiratory efforts and exercise intolerance were the most common presenting clinical signs, followed by syncope.\textsuperscript{5,25} Moreover, 76.7\% of dogs with respiratory problems also had gastrointestinal clinical signs, specially vomiting and regurgitation.\textsuperscript{7,22,25,45,46} Although it is not frequently described, SDB may be consequence of BAOS.\textsuperscript{17,48} Indeed, sleep is thought to exacerbate BAOS because the muscles that dilate the upper airways relax.\textsuperscript{2} Sleep-disordered breathing has been described
in Pugs, French Bulldogs, English Bulldogs and, more recently, in Cavalier King Charles Spaniels.\textsuperscript{17,30,49} In our study, more than half of the dogs showed clinical signs of SDB. However, without polysomnography and follow-up information, it is not possible to better characterize SDB and conclude that BAOS at least contributed to sleep apnea.\textsuperscript{17,50} With regard to the airway anatomic abnormalities, our findings were consistent with those of other studies, but a higher number of dogs showed laryngeal collapse (86.6\%).\textsuperscript{9,25,45} Tracheal and bronchial collapse were detected only in a minority of dogs (13.8\%). These results are not surprising because laryngeal collapse is considered a common secondary functional change occurring in brachycephalic dogs, along with pharyngeal and tonsillar hyperplasia and bronchial collapse.\textsuperscript{47,51,52} However, the severity of respiratory and digestive clinical signs seen at presentation and at the time of radiography and endoscopy was not influenced by the number of anatomic abnormalities or severity of laryngeal collapse, whereas a correlation between laryngeal collapse and bronchial abnormalities has already been described elsewhere.\textsuperscript{52} This lack of relationship, however, could be explained by the presence of other anomalies that are not routinely evaluated, such as obstructing turbinates, deviation of the nasal septum or narrowing or distortion of the retropharyngeal space, in addition to a different combination of anatomic abnormalities and breed-specific anatomical airway differences.\textsuperscript{53-55}

As reported elsewhere, esophageal deviation, distal esophagitis, atony of the cardia of the stomach, gastric stasis, pyloric mucosal hyperplasia, and gastrointestinal inflammation were the most common endoscopic anomalies recorded, although esophageal deviation and pyloric mucosal hyperplasia were observed more and less frequently, respectively.\textsuperscript{25} Gastro-esophageal reflux and hiatal hernia were not identified. However, considering that sliding hiatal hernia is by far the most frequently observed in dogs and its frequency is underestimated by radiography or endoscopy, it cannot be definitively excluded here. In addition, hiatal hernia may not have been
diagnosed because of the effects of tracheal intubation and anesthesia.\textsuperscript{4,7} Finally, the gastrointestinal tract of dogs without digestive signs was not evaluated, although brachycephalic dogs may have mild digestive anomalies and inflammation even without having digestive signs.\textsuperscript{25}

Consistent with available data, histologic evaluation of the stomach and duodenum identified mostly chronic inflammation,\textsuperscript{25,45} in addition to lacteal dilatation, not previously reported. Because brachycephalic breeds are not overrepresented among dogs with intestinal lymphangiectasia, it can be hypothesized that the lacteal dilatation could have been a consequence of chronic gastrointestinal inflammation, rather than a primary gastrointestinal problem.\textsuperscript{56} However, it cannot be determined because a specific diagnostic evaluation of intestinal signs was not undertaken. To our knowledge, ours is the first prospective clinical study of dogs with BAOS that has evaluated parameters of glucose regulation and lipid profiles and their relationship with clinical signs and anatomical abnormalities. Glucose, fructosamine, total cholesterol and triglyceride concentrations were increased in variable proportions in dogs in our study. In human medicine, an association between OSAS and insulin resistance was observed in some studies, whereas it was not clear in others.\textsuperscript{57} Moreover, SDB can be the cause of notable glycemic variability, which in turn is associated with complications of diabetes.\textsuperscript{58} However, no relationship between increased blood glucose concentrations and severity of OSAS was detected in non-diabetic patients, as in dogs with BAOS described here.\textsuperscript{59} Increased fructosamine concentrations were observed in almost one-third (32.1\%) of the dogs, whereas hyperglycemia was only found in a smaller proportion (14\%). Because hyperproteinemia as a possible cause of increased fructosamine concentrations was ruled out, this discrepancy might be explained by the presence of intermittent hyperglycemia, perhaps related to surges in sympathetic activity secondary to respiratory distress.\textsuperscript{34,36} None of the dogs in our study
had hyperinsulinemia, whereas decreased serum insulin concentrations were observed in almost all dogs (92.6%). Because no evidence of any other diseases was found in dogs included in the study, lower than normal serum insulin concentrations were considered to be caused by pre-anesthesia fasting. The majority of studies in human medicine suggests that triglyceride but not total cholesterol concentrations are increased in OSAS patients, and that continuous airway pressure has a positive effect on lowering the serum concentrations of both analytes.\textsuperscript{60,61} Total cholesterol and triglyceride concentrations were normal in approximately 70% of the dogs studied here, whereas lipoprotein classes were increased in the majority of the dogs, perhaps suggesting that serum lipoprotein electrophoresis is more accurate in detecting dyslipidemia in dogs than are total cholesterol and triglyceride concentrations.\textsuperscript{62} In veterinary medicine, a gold standard validated method for the evaluation of canine lipoproteins is currently lacking, and many published reports have utilized automated electrophoretic protocols developed for human use, as in our study.\textsuperscript{63-65} However, the electrophoresis method used here was selected because some studies have documented that it might be more accurate than the wet chemistry method for identifying some lipoprotein classes, especially low-density lipoproteins, which are substantial in dogs.\textsuperscript{63,66} The alpha fraction is the sum of the pre-alpha, alpha-1 and alpha-2 components and is predominant in normal dogs, and the canine high-density lipoproteins (HDL) seem to show this migratory pattern.\textsuperscript{67,68} In veterinary medicine, to date, a decrease in low-density lipoproteins (LDL) was reported in chronic kidney disease, nephrotic syndrome and pancreatitis in dogs.\textsuperscript{67,69,70} In our study, these lipoprotein classes were normal in the majority of the dogs (80%) whereas the pre-beta and beta classes, corresponding to the very low density lipoproteins (VLDL) and LDL, respectively, and the chylomicrons, were increased in more than half of the dogs.\textsuperscript{68} In
veterinary medicine, to date, both classes are increased in chronic kidney disease, nephrotic syndrome, diabetes mellitus and pancreatitis.\textsuperscript{66,69-71}

Limited information exists in dogs with BAOS with regard to the systemic inflammatory response. C-reactive protein concentration was found to be increased in 14\% of dogs, but no statistical correlation was found with severity of clinical signs or after surgery.\textsuperscript{22,24}

In another study, some proinflammatory cytokines and nitric oxide were found to be higher in brachycephalic dogs than control dogs and to be associated with disease severity.\textsuperscript{23} In our study, half of the dogs showed increased CRP concentrations, suggesting that a systemic inflammatory response might be common in dogs with BAOS.

Our study failed to identify a significant association between severity of clinical signs and anatomic abnormalities, inflammatory response, parameters of glucose regulation and lipid profiles.

Our study had some limitations, primarily related to relatively small sample size, considering the different degrees of BAOS severity addressed. Other limitations were that the quantitative scoring system was assessed by a single observer at each center and therefore was somewhat subjective, gastroduodenal endoscopy was only performed in dogs with gastrointestinal signs, and polysomnography and exercise testing were not performed to better characterize SDB and improve BAOS’s assessment.\textsuperscript{50,72} Moreover, it was not possible to include a control group in our study because of the difficulty in findings brachycephalic dogs with normal breathing pattern. Nearly all brachycephalic dogs have some degree of upper airway obstruction.\textsuperscript{2,72} Lastly, information about the gold standard method for lipoprotein evaluation as well as the pathophysiology of their metabolism in dogs is lacking. Without this information, the clinical utility of some data presented here is unknown and cannot be interpreted reliably.
In conclusion, it seems that the clinicopathological variables considered do not offer valuable information in dogs with BAOS. On the other hand, however, the presence of an inflammatory response and some mild metabolic derangements suggest the need to further explore the metabolic profile and inflammatory status of dogs with BAOS using studies including more animals with similar degrees of BAOS severity.

References

1. Meola SD. Brachycephalic airway syndrome. *Top Companion Anim Med*. 2013; 28: 91-96
2. Dupré G, Heindrenreich D. Brachycephalic syndrome. *Vet Clin north Am Small Anim Pract*. 2016; 46: 691-707
3. White DR, Heavner SB, Hardy SM, Prazma J. Gastroesophageal reflux and eustachian tube dysfunction in an animal model. *Laryngoscope*. 2002; 112: 955-961
4. Broux O, Clercx C, Etienne AL, et al. Effects of manipulation to detect sliding hiatal hernia in dogs with brachycephalic airway obstructive syndrome. *Vet Surg*. 2018, 47: 243-251
5. Haimel G, Dupré G. Brachycephalic airway syndrome: a comparative study between pugs and French bulldogs. *J Small Anim Pract*. 2015; 56: 714-719
6. Roedler FS, Pohl S, Oechtering GU. How does severe brachycephaly affect dog’s lives? Results of a structured preoperative owner questionnaire. *Vet J*. 2013; 198: 606-610
7. Reeve EJ, Sutton D, Friend EJ, Warren-Smith CMR. Documenting the prevalence of hiatal
hernia and oesophageal abnormalities in brachycephalic dogs using fluoroscopy. *J Small Anim Pract.* 2017; 58: 703-708

8. Torrez CV, Hunt GB. Results of surgical correction of abnormalities associated with brachycephalic airway obstruction syndrome in dogs in Australia. *J Small Anim Pract.* 2006; 47: 150-154

9. Rieks TW, Bichard SJ, Stephens JA. Surgical correction of brachycephalic syndrome in dogs: 62 cases (1991-2004). *J Am Vet Med Assoc.* 2007; 230: 1324-1328

10. Liu NC, Genain MA, Kalmar L, et al. Objective effectiveness of and indications for laser-assisted turbinectomy in brachycephalic obstructive airway syndrome. *Vet Surg.* 2019; 48: 79-87

11. Butt M, Dwivedi G, Khair O, Lip GY. Obstructive sleep apnea and cardiovascular disease. *Int J Cardiol.* 2010; 139: 7-16

12. Lindberg E, Gislason T. Epidemiology of sleep-related obstructive breathing. *Sleep Med Rev.* 2000; 4: 411-433

13. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med.* 1993; 29; 328: 1230-1235

14. Sanner BM, Konermann M, Tepel M, et al. Platelet function in patients with obstructive sleep apnoea syndrome. *Eur Respir J.* 2000; 16: 648-652
15. Punjabi NM, Polotsky VY. Disorders of glucose metabolism in sleep apnea. *J Appl Physiol.* 2005; 99: 1998–2007

16. Togeiro SM, Carneiro G, Ribeiro Filho FF, et al. Consequences of obstructive sleep apnea on metabolic profile: A population-based survey. *Obesity* 2013; 21: 847-851

17. Hendricks JC, Kline LR, Kovalski RJ, et al. The English bulldog: a natural model of sleep disordered breathing. *J Appl Physiol.* 1987; 63: 1344-1350

18. Hendricks JC, Kovalski RJ, Kline LR. Phasic respiratory muscle patterns and sleep disordered breathing during rapid eye movement sleep in the English bulldog. *Am Rev Respir Dis.* 1991; 144: 1112-1120

19. Crane C, Rozanski EA, Abelson AL, deLaforcade A. Severe brachycephalic obstructive airway syndrome is associated with hypercoagulability in dogs. *J Vet Diagn Invest.* 2017; 29: 570-573

20. Liu NC, Oechtering GU, Adams VJ, et al. Outcomes and prognostic factors of surgical treatments for brachycephalic obstructive airway syndrome in 3 breeds. *Vet Surg.* 2017; 46: 271-280

21. Kaye BM, Boroffka SA, Haagsman AN, Ter Haar G. Computed tomographic, radiographic, and endoscopic tracheal dimensions in english bulldogs with grade 1 clinical signs of
brachycephalic airway syndrome. *Vet Radiol Ultrasound.* 2015; 56: 609-616

22. Planellas M, Cuenca R, Tabar MD, et al. Clinical assessment and C-reactive protein (CRP), haptoglobin (Hp), and cardiac troponin I (cTnI) values of brachycephalic dogs with upper airway obstruction before and after surgery. *Can J Vet Res.* 2015; 79: 58-63

23. Rancan L, Romussi S, Garcia P, et al. Assessment of circulating concentrations of proinflammatory and anti-inflammatory cytokines and nitric oxide in dogs with brachycephalic airway obstruction syndrome. *Am J Vet Res.* 2013; 74: 155-160

24. Planellas M, Cuenca R, Tabar MD, et al. Evaluation of C-reactive protein, haptoglobin and cardiac troponin I levels in brachycephalic dogs with upper airway obstructive syndrome. *BMC Vet Res.* 2012; 8: 152

25. Poncet CM, Dupre GP, Freiche VG, et al. Prevalence of gastrointestinal tract lesions in 73 brachycephalic dogs with upper respiratory syndrome. *J Small Anim Pract.* 2005; 46: 273,279

26. Laflamme D. Development and validation of a body condition score system for dogs. *Canine Pract,* 1997; 22: 10-15

27. Rawlings CA. Diagnostic rigid endoscopy: otoscopy, rhinoscopy and cystoscopy. *Vet Clin North Am Small Anim Pract.* 2009; 39: 849-868

28. Creevy KE Airway evaluation and flexible endoscopic procedures in dogs and cats:
laryngoscopy, transtracheal wash, tracheobronchoscopy, and bronchoalveolar lavage. Vet Clin North Am Small Anim Pract. 2009; 39: 869-880

29. Sum S, Ward CR Flexible endoscopy in small animals. Vet Clin North Am Small Anim Pract. 2009; 39: 881-902

30. Hendricks JC: Brachycephalic airway syndrome. Vet Clin North Am Small Anim Pract. 1992; 22: 1145-1153

31. Harvey CE, Fink EA. Tracheal diameter analysis of radiographic measurement in brachycephalic and nonbrachycephalic dogs. J Am Vet Med Assoc. 1982; 18: 570-576

32. Leonard HC. Collapse of the larynx and adjacent structures in the dog. J Am Vet Med Assoc. 1960; 137: 360-363

33. Allenspach KA, Mochel JP, Du Y, et al. Correlating gastrointestinal histopathologic changes to clinical disease activity in dogs with idiopathic inflammatory bowel disease. Vet. Pathol. 2018; DOI: 10.1177/0300985818813090

34. Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Medicine Clinics. 2007; 2: 263-277

35. Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Progress in Lipid Research. 2009; 48: 275-297

36. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine. 2005; 11: 183-190
37. Packer RM, Tivers M. Strategies for the management and prevention of conformation-related respiratory disorders in brachycephalic dogs. *Vet Med Res Reports*. 2015; 6: 219-232

38. Hoareau GL, Jourdan G, Mellema M, Verwaerd P. Evaluation of arterial blood gases and arterial blood pressures in brachycephalic dogs. *J Vet Intern Med*, 2012; 26: 897-904

39. Grand JG, Bureau S. Structural characteristics of the soft palate and meatus nasopharyngeus in brachycephalic and nonbrachycephalic dogs analysed by CT. *J Small Anim Pract*. 2011; 52: 232-239

40. Liu NC, Adams VJ, Kalmar L, et al. Whole-body barometric plethysmography characterizes upper airway obstruction in 3 brachycephalic breeds of dogs. *J Vet Intern Med*. 2016; 30: 853-865

41. Cizza G, de Jonge L, Piaggi P, et al. Neck circumference is a predictor of metabolic syndrome and obstructive sleep apnea in short-sleeping obese men and women. *Metab Syndr Relat Disord* 2014; 12: 231-241

42. Mortimore I, Marshall I, Wraith P, et al. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. *Am J Respir Crit Care Med*. 1998; 157: 280-283

43. Packer RMA, Hendricks A, Tivers MS, Burn CC. Impact of facial conformation on canine health: brachycephalic obstructive airway syndrome. *PLOS one*, 2015; 28: 1-21

44. Liu NC, Troconis EL, Kalmar L, et al. Conformational risk factors of brachycephalic obstructive airway syndrome (BOAS) in Pugs, French bulldogs, and bulldogs. *PLOS one* 2017; 12: 1-24
45. Poncet CM, Dupre GP, Freiche VG, Bouvy BM. Long-term results of upper respiratory syndrome surgery and gastrointestinal tract medical treatment in 51 brachycephalic dogs. *J Small Anim Pract*. 2006; 47: 137-142

46. Kaie BM, Rutherford L, Perridge DJ, ter Haar G. Relationship between brachycephalic airway syndrome and gastrointestinal signs in three breeds of dogs. *J Small Anim Pract*. 2018; 59: 670-673

47. Monnet E. Brachycephalic airway syndrome. In: Textbook of Small Animal Surgery. Ed D. Slatter. Philadelphia: W.B. Saunders; 2003: 808-813

48. Pohl S, Roedler FS, Oechtering GU. How does multilevel upper airway surgery influence the lives of dogs with severe brachycephaly? Results of a structured pre- and postoperative owner questionnaire. *Vet J*. 2016; 210: 39-45

49. Hinchliffe TA, Liu N-C, Ladlow J. Sleep-disordered breathing in the Cavalier King Charles spaniel: A case series. *Vet Surg*. 2019; 48: 497–504

50. Kis A, Szakadát S, Kovács E, et al. Development of a noninvasive polysomnography technique for dogs (Canis familiaris). *Physiol Behav*. 2014; 130: 149–156

51. Aron DN, Crowe DT. Upper airway obstruction. General principles and selected conditions in the dog and cat. *Vet Clin North Am Small Anim Pract*. 1985; 15: 891-917

52. De Lorenzi D, Bartoncello D, Drigo M. Bronchial abnormalities found in a consecutive series of 40 brachycephalic dogs. *J Am Vet Med Assoc*. 2009; 235: 835-840
53. Caccamo R, Buracco P, La Rosa G, et al. Glottic and skull indices in canine brachycephalic airway obstructive syndrome. *BMC Vet Res*. 2014; 10:12

54. Oechtering GU, Pohl S, Schlüeter C, et al. Novel approach to brachycephalic syndrome. 1 Evaluation of anatomical intranasal airway obstruction. *Vet Surg*. 2016; 45: 165-172

55. Heidenreich D, Gradner G, Kneissl S, Dupré G. Nasopharyngeal dimensions from computed tomography of pugs and french bulldogs with brachycephalic airway syndrome. *Vet Surg*. 2016; 45: 83-90.

56. Peterson PB, Willard MD. Protein-losing enteropathies. *Vet Clin North Am Small Anim Pract*. 2003; 33: 1061-1082

57. Punjabi NM, Shahar E, Redline S, et al. Sleep disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. *Am J Epidemiol*. 2004; 160: 521-30

58. Passali D, Tatti P, Passali FM, et al. The undisclosed role of disturbed sleep and hypoxia on metabolism: the importance of upper airways pathology. *Sleep Breath*. 2013;17: 5-6

59. Söküçü SN, Karasulu L, Dalar L, et al. Effect of hypoxia on glucose metabolism in nondiabetic patients with obstructive sleep apnea syndrome. *Arch Bronconeumol*. 2013; 49: 321-325

60. Drager LF, Bortolotto LA, Figueiredo AC, et al. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med*. 2007; 176: 706-712
61. Roche F, Sforza E, Pichot V, et al. Obstructive sleep apnoea / hypopnea influences high density lipoprotein cholesterol in the elderly. *Sleep Med.* 2009; 10: 882-886

62. Behling-Kelly E, Collins-Cronkright R. Increases in beta-lipoproteins in hyperlipidemic and dyslipidemic dogs are associated with increased erythrocyte osmotic fragility. *Vet Clin Pathol.* 2014; 43: 405-415

63. Behling-Kelly E. Comparison of 2 electrophoretic methods and a wet-chemistry method in the analysis of canine lipoproteins. *Vet Clin Pathol.* 2016; 45: 124-134

64. Yilmaz Z, Senturk S. Characterization of lipid profiles in dogs with parvoviral enteritis. *J Small Anim Pract.* 2007; 48:643-650

65. Rossi G, Kules J Rafaj RB, et al. Relationship between paraxonase 1 activity and high density lipoprotein concentration during naturally occurring babesiosis in dogs. *Res Vet Sci.* 2014; 22: 00212-00214

66. Behling-Kelly E. Serum lipoprotein changes in dogs with renal disease. *J Vet Inter Med.* 2014; 28: 1692-1698

67. Mori N, Lee P, Kondo K, et al. Potential use of cholesterol lipoprotein profile to confirm obesity status in dogs. *Vet Res Commun.* 2011; 35: 223-235

68. Mahley RW, Weisgraber KH. Canine lipoproteins and atherosclerosis. Isolation and
characterization of plasma lipoproteins from control dogs. *Circ Res*. 1974; 35: 713-721

69. Whitney MS, Boon GD, Rebar AH, Ford RB. Effects of acute pancreatitis on circulating lipids in dogs. *Am J Vet Res*. 1987; 48: 1492-1497

70. Whitney MS, Boon GD, Rebar AH, et al. Ultracentrifugal and electrophoretic characteristics of the plasma lipoproteins of miniature Schnauzer dogs with idiopathic hyperlipoproteinemia. *J Vet Intern Med*. 1993; 7: 253-260

71. Rogers WA, Donovan EF, Kociba GJ. Lipids and lipoproteins in normal dogs and in dogs with secondary hyperlipidemia. *J Am Vet Med Assoc*. 1975; 166: 1092-1100

72. Riggs MA, Nai-Chien L, Dawn R. et al. Validation of exercise testing and laryngeal auscultation for grading brachycephalic obstructive airway syndrome in pugs, French bulldogs, and English bulldogs by using whole-body barometric plethysmography. *Vet Surg* 2019; 48: 488-496
Table 1. Cholesterol, triglyceride, glucose, total protein, fructosamine, insulin and C-reactive protein serum concentration results

| Variables            | Median values (range) | Mean values (±SD) | Normal values % (n/t) | Values above the R.R. % (n/t) | Values below the R.R. % (n/t) |
|----------------------|-----------------------|-------------------|-----------------------|-------------------------------|-------------------------------|
| Cholesterol          | 210.5 mg/dL (101-373) | 221.8 mg/dL (±68.3) | 73.4% (22/30)         | 20% (6/30)                    | 6.6% (2/30)                   |
| Triglyceride         | 88.5 mg/dL (29-208)   | 101.2 mg/dL (±50.0) | 67.9% (19/28)         | 32.1% (9/28)                  | -                             |
| Glucose              | 100.5 mg/dL (72-227)  | 102.6 mg/dL (±27.8) | 85.7% (24/28)         | 14.3% (4/28)                  | -                             |
| Total Protein        | 5.6 g/dL (4.5-7.3)    | 5.7 g/dL (±0.8)    | 65.5% (19/29)         | -                             | 34.5% (10/29)                 |
| Fructosamine         | 237 µmol/L (100-329)  | 241.5 µmol/L (±52.1)| 64.3% (18/28)         | 32.1% (9/28)                  | 3.6% (1/28)                   |
| Insulin              | 1.9 µU/ml (1.9-10.8)  | 2.5 (±2.0)         | 7.4% (2/27)           | -                             | 92.6% (25/27)                 |
| C-reactive protein   | 0.6 mg/dL (0.0-19.10.10) | 1.7 mg/dL (±3.8) | 48.1% (13/27)         | 51.9% (14/27)                 | -                             |

n=number of dogs in which the variable was normal, above or below the reference range
t=total number of dogs

R.R.= reference range

SD=standard deviation

Table 2. Plasma lipoprotein electrophoresis results

| Lipoprotein classes (R.R.) | Median values (range) | Mean values (±SD) | Normal values % (n/t) | Values above the R.R. % (n/t) | Values below the R.R. % (n/t) |
|---------------------------|-----------------------|-------------------|-----------------------|-------------------------------|-----------------------------|
| Prealfa (pα) (.8-2.5%)    | 1.8% (0.9-9.1)        | 2.3% (±1.8)       | 80% (16/20)           | 20% (4/20)                    | -                           |
| Alfa 1 (α1) (30.9-40.6%)  | 32.6% (25.6-43)       | 32.7% (±3.7)      | 75% (15/20)           | 5% (1/20)                     | 20% (4/20)                  |
| Alfa 2 (α2) (21.5-35.0%)  | 25.2% (17.5-33.6)     | 25.8 (±4.5)       | 85% (17/20)           | -                             | 15% (3/20)                  |
| Prebeta (pβ) (4.9-11.0%)  | 12.9% (5.4-23.6)      | 13.8 (±5.9)       | 40% (8/20)            | 60% (12/20)                   | -                           |
| Beta (β) (11.1-19.0)      | 19.7% (10.8-26.0)     | 18.7 (±4.7)       | 40% (8/20)            | 55% (11/20)                   | 5% (1/20)                   |
| Chylomicrons (κ) (1.3-3.4)| 5.7% (1.6-16.2)       | 6.7 (±4.1)        | 35% (7/20)            | 65% (13/20)                   | -                           |

R.R.= reference range
n=number of dogs in which the lipoprotein class was normal, above or below the reference range

t=total number of dogs

SD=standard deviation

Table 3. Results of univariate analysis

| Variables   | Symptomatic score |       |       |       |       |
|-------------|-------------------|-------|-------|-------|-------|
|             | score≤4 | score≥5 | Total |       | P     |
| Breed       |         |         |       |       |       |
| French bulldogs | 6   | 7   | 13   |       | .75   |
| English bulldogs | 2   | 5   | 7    |       |       |
| Pugs        | 4       | 6     | 10   |       |       |
| Sex         |         |       |       |       |       |
| Male        | 8       | 14    | 22   |       | .68   |
| Female      | 4       | 4     | 8    |       |       |
| BCS         |         |       |       |       |       |
| ≤ 6         | 7       | 6     | 13   |       | .26   |
| > 6         | 5       | 12    | 17   |       |       |
| Body weight (kg) | ≤ 11.7 | 7   | 8    | 15   | .71   |
|                          | ≤ 36 | 6   | 12  | 18  | .46  |
|--------------------------|------|-----|-----|-----|------|
| Age (months)             |      |     |     |     |      |
|                          | > 36 | 6   | 6   | 12  |      |
| MAP (mm/Hg)              |      |     |     |     |      |
| ≤ 70                     | 7    | 3   | 10  | .05<sup>a</sup> |
| > 70                     | 5    | 15  | 20  |      |
| SpO<sub>2</sub>          |      |     |     |     |      |
| ≤ 98                     | 7    | 4   | 11  | .06<sup>a</sup> |
| > 98                     | 5    | 14  | 19  |      |
| Quantitative anatomical score |      |     |     |     |      |
| ≤ 6                      | 8    | 9   | 17  | .47  |
| > 6                      | 4    | 9   | 13  |      |
| Night time arousal       |      |     |     |     |      |
| never                    | 5    | 5   | 10  | .72  |
| mild                     | 4    | 8   | 12  |      |
| moderate/severe          | 3    | 5   | 8   |      |
| Respiratory signs and attitude after arousals |      |     |     |     |      |
| present                  | 10   | 11  | 11  | .25  |
| absent                   | 2    | 7   | 9   |      |
| Owner’s perception that sleep disruption was caused by airway obstruction | 7 | 6 | 13 | .26 |
|                         | absent | 5   | 12  | 17  | 28  | .50 |
|-------------------------|--------|-----|-----|-----|-----|-----|
| Abnormal sleeping positions | present | 12  | 16  | 28  | .50 |
|                         | absent  | 0   | 2   | 2   |
| Presence of at least 1 clinical sign or abnormal attitude during sleep | yes    | 5   | 5   | 10  | .46 |
|                         | no      | 7   | 13  | 20  |
| Laryngeal collapse score | ≤ 2     | 5   | 7   | 12  | 1   |
|                         | > 2     | 7   | 10  | 17  |
| Cholesterol (mg/dL)     | ≤ 210.5 | 8   | 7   | 15  | .26 |
|                         | > 210.5 | 4   | 11  | 15  |
| Triglyceride (mg/dL)    | ≤ 88.5  | 8   | 7   | 15  | .26 |
|                         | > 88.5  | 4   | 11  | 15  |
| Total protein (g/dL)    | ≤ 5.6   | 5   | 10  | 15  | .71 |
|                         | > 5.6   | 7   | 8   | 15  |
| Glucose (mg/dL)         | ≤ 100.5 | 6   | 8   | 14  | 1   |
|                         | > 100.5 | 6   | 10  | 16  |
| Parameter                              | Range 1 | Range 2 | Range 3 | Range 4 | Range 5 |
|----------------------------------------|---------|---------|---------|---------|---------|
| C-reactive protein (mg/dL)             | ≤ .55   | 7       | 7       | 14      | .46     |
|                                        | > .55   | 5       | 11      | 16      |         |
| Fructosamine (umol/L)                  | ≤ 237   | 6       | 8       | 14      | 1       |
|                                        | > 237   | 6       | 10      | 16      |         |
| Insulin (µU/ml)                        | ≤ 1.9   | 9       | 14      | 23      | 1       |
|                                        | ≥ 2.0   | 3       | 4       | 7       |         |
| Prealpha (%)                           | ≤ 1.80  | 7       | 5       | 12      | .14 a   |
|                                        | > 1.80  | 5       | 13      | 18      |         |
| Alpha 1 (%)                            | ≤ 32.60 | 6       | 4       | 10      | .14 a   |
|                                        | > 32.60 | 6       | 14      | 20      |         |
| Alpha 2 (%)                            | ≤ 25.25 | 3       | 7       | 10      | .69     |
|                                        | > 25.25 | 9       | 11      | 20      |         |
| Prebeta (%)                            | ≤ 12.95 | 5       | 5       | 10      | .46     |
|                                        | > 12.95 | 7       | 13      | 20      |         |
| Beta 1 (%)                             | ≤ 19.75 | 5       | 5       | 10      | .46     |
|                                        | > 19.75 | 7       | 13      | 20      |         |
| Chylomicrons (%) | ≤ 5.70 | 4 | 6 | 10 | 1 |
|-----------------|--------|---|---|----|---|
|                 | > 5.70 | 8 | 12| 20 |   |

*Statistical association* \( P < .20 \)

Table 4. Results of logistic regression analysis

| Factors | Dogs with symptomatic score ≥5/total (%) | OR | 95% CI for OR | \( P \) |
|---------|-----------------------------------------|----|---------------|-------|
| MAP     |                                         |    |               |       |
| ≤70     | 3/10 (30.0)                             | -  |               |       |
| >70     | 15/20 (75.0)                            | 4.45| .31-64.87     | .27 |
| SPO2    |                                         |    |               |       |
| ≤112    | 4/11 (36.4)                             | -  |               |       |
| >112    | 14/19 (73.7)                            | 1.02| .07 - 14.00   | .99 |
|        | Prealpha                      | Alpha 1                      |
|--------|-------------------------------|------------------------------|
| ≤2.46  | 5/12 (41.7)                  | 4/10 (40.0)                 |
| >2.46  | 13/18 (72.2)                 | 14/20 (70.0)                |
|        | 2.16                          | 1.97                        |
|        | .46 – 14.72                  | .32 – 12.15                 |
|        | .28                           | .46                         |
|        |                               | Constant                    |
|        |                               | .01                         |
|        |                               | .03                         |
